We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Affymetrix, Inc. | NASDAQ:AFFX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.01 | 0 | 01:00:00 |
Shares of Santa Clara, Calif.-based biomedical company Affymetrix Inc. (AFFX) spiked 11.5% following the release of its 2013-fourth quarter revenue guidance that exceeded estimates. Shares of the company closed at $8.81, represented a whopping one-year return of nearly 160.0%.
AFFX revealed that it anticipates fourth quarter revenues of $91.0 million, including a one-time licensing payment of $5.3 million from a diagnostic partner. For fiscal 2013, the company expects total revenue of roughly $329.0 million.
Both the quarterly and annual estimates surpassed the Zacks Consensus Estimate of $85 million and $322 million, respectively. The quarterly sales also reflect a 7.8% rise from the year-ago level of $84.4 million.
Affymetrix posted adjusted earnings per share of 5 cents in the third quarter of 2013, surpassing the Zacks Consensus Estimate of 2 cents and rebounding from the year-ago adjusted loss of 3 cents.
Revenues inched up 0.9% to $80.4 million, beating the Zacks Consensus Estimate of $79 million. Product revenues improved 2.9% to $74.8 million, while Service and other revenues dropped 18.8% to $5.6 million in the reported quarter.
Gross margin surged 300 basis points (bps) to 55% from 52% in the third quarter of 2012. However, on an adjusted basis, gross margin increased 100 bps to 61%.
We believe that AFFX is ready for a turn around and the worst days are over for the company. In the face of declining demand for Affymetrix’ flagship GeneChip Expression products, management strategy to transform AFFX into a company with a broad reach in the high-growth markets for translational medicine, molecular diagnostics and applied markets is indeed encouraging.
Currently, AFFX retains a Zacks Rank #1 (Strong Buy). Other players in the biomed/gene industry, which also look attractive at present, include Alimera Sciences, Inc. (ALIM), Genomic Health Inc. (GHDX), and Horizon Pharma, Inc. (HZNP). All of them carry a Zacks Rank #1 (Strong Buy).
1 Year Affymetrix Chart |
1 Month Affymetrix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
